文献速递肺血管病与心包/心肌炎

生长分化因子-15作为成人肺动脉高压死亡预测因子的研究

Growth differentiation factor-15 as candidate predictor for mortality in adults with pulmonary hypertension.
PubMed 文献 · Heart · 2019-09-06

这项单中心前瞻性观察队列研究纳入103例成人肺动脉高压患者,在诊断性右心导管检查日测量静脉血GDF-15和NT-proBNP。中位随访3.4年,32例(31.1%)达到死亡或肺移植复合终点;GDF-15升高与终点风险增加独立于年龄和NT-proBNP相关,正常GDF-15患者2年无事件生存率100%。

要点

  • GDF-15升高与肺动脉高压患者死亡或肺移植风险增加独立相关。
  • 正常GDF-15患者2年无事件生存率100%,有助于识别低危患者。
  • GDF-15为非特异性生物标志物,可作为NT-proBNP之外的补充预测指标。

核心结论

  • 高GDF-15水平与成人肺动脉高压患者死亡或移植风险增加相关,且独立于年龄和NT-proBNP。
  • GDF-15作为非特异性生物标志物,可能特别有助于识别低危患者。

研究设计与样本

  • 单中心前瞻性观察队列研究,纳入2012至2016年间诊断性右心导管检查的成人肺动脉高压患者,排除左心疾病所致肺动脉高压。
  • 共测量103例患者(中位年龄59.2岁,65%女性,51%肺动脉动脉高压)的静脉血GDF-15和NT-proBNP,并以健康对照建立参考值。
  • 采用Kaplan-Meier曲线和Cox回归分析GDF-15与死亡或肺移植复合终点的关联,多变量分析调整年龄和NT-proBNP。

主要发现

  • 76例(74%)患者GDF-15升高。
  • 中位随访3.4年(IQR 2.3-4.6),32例(31.1%)达到主要终点。
  • 诊断后2年无事件生存率:GDF-15正常患者100%,GDF-15升高患者72.4%(p=0.007)。
  • GDF-15与主要终点显著相关(每升高两倍HR 1.77,95%CI 1.39-2.27,p<0.001),调整年龄和NT-proBNP后仍显著(HR 1.41,95%CI 1.02-1.94,p=0.038)。

临床怎么用

  • 在肺动脉高压患者中可考虑检测GDF-15,辅助风险分层,尤其用于识别低危患者。
  • GDF-15升高提示死亡或移植风险增加,可结合NT-proBNP等指标综合评估。

局限性

  • 单中心研究,样本量有限(103例),结果需多中心验证。
  • GDF-15为非特异性生物标志物,可能受其他疾病影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Despite its predictive value for mortality in various diseases, the relevance of growth differentiation factor-15 (GDF-15) as prognostic biomarker in pulmonary hypertension (PH) remains unclear. This study investigated the association between GDF-15 and outcomes in adults with PH. METHODS: This is a single-centre prospective observational cohort study. All adults with PH were included at the day of their diagnostic right heart catheterisation between 2012 and 2016. PH due to left heart disease was excluded. Venous blood sampling was performed and included GDF-15 and N-terminal pro-B-type natriuretic peptide (NT-proBNP) measurements. Kaplan-Meier curves and Cox regression analysis were used to investigate the association between GDF-15 and a composite endpoint of death or lung transplantation. We adjusted for age and NT-proBNP in multivariable analysis. Reference values were established by GDF-15 measurements in healthy controls. RESULTS: GDF-15 was measured in 103 patients (median age 59.2 years, 65% women, 51% pulmonary arterial hypertension). GDF-15 was elevated in 76 patients (74%). After a median follow-up of 3.4 (IQR 2.3-4.6) years, 32 patients (31.1%) reached the primary endpoint. Event-free survival 2 years after diagnosis was 100% in patients with normal GDF-15 versus 72.4% in patients with elevated GDF-15 (p=0.007). A significant association was found between GDF-15 and the primary endpoint (HR per twofold higher value 1.77, 95% CI 1.39 to 2.27, p<0.001), also after adjustment for age and NT-proBNP (HR 1.41, 95% CI 1.02 to 1.94, p=0.038). CONCLUSIONS: High GDF-15 levels are associated with an increased risk of death or transplant in adults with PH, independent of age and NT-proBNP. As non-specific biomarker, GDF-15 could particularly be useful to detect low-risk patients.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Geenen LW, Baggen VJM, Kauling RM, et al. Growth differentiation factor-15 as candidate predictor for mortality in adults with pulmonary hypertension. Heart. 2019. PMID: 31492701. doi:10.1136/heartjnl-2019-315111

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。